期刊文献+

共刺激分子在原发性胆汁淤积性肝硬化中的研究进展 被引量:1

下载PDF
导出
摘要 原发性胆汁性肝硬化(primary biliary cirrhosis,PBC)是一种慢性渐进性自身免疫性肝病,特征是汇管区淋巴细胞浸润和胆管上皮细胞的选择性破坏^([1-3])。90%~95%PBC患者血清中都会出现高低度抗线粒体抗体(anti-mitochondrial antibody,AMA)阳性。PBC病因不明,可能是环境、免疫紊乱、遗传变异等多种因素共同作用的结果。研究表明PBC的发生与T细胞的异常活化有关。
出处 《中国医药生物技术》 2015年第6期544-546,550,共4页 Chinese Medicinal Biotechnology
基金 江苏省常州市卫生局重大科技项目(ZD201108) 国家自然科学基金青年科学基金(K11245213)
  • 相关文献

参考文献46

  • 1Hirschfield GM, Gershwin ME. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol, 2013, 8:303-330.
  • 2Liaskou E, Hirschfield GM, Gershwin ME. Mechanisms of tissue injury in autoimmune liver diseases. Semin Immunopathol, 2014, 36(5):553-568.
  • 3Wang L, Wang FS, Chang C, et al. Breach of tolerance: primary biliary cirrhosis. Semin Liver Dis, 2014, 34(3):297-317.
  • 4黄芳,莫雪安.共刺激分子与重症肌无力[J].神经损伤与功能重建,2007,2(2):85-89. 被引量:1
  • 5Kirchhoff S, Muller WW, Li-Weber M, et at. Up-regulation of c-FLIPshort and reduction of activation-induced cell death in CD28-costimulated human T cells. Eur J Immunol, 2000, 30(10): 2765-2774.
  • 6Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science, 1995, 270(5238):985-988.
  • 7Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lympboproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity, 1995, 3(5):541-547.
  • 8Krummel MF, Allison JP. CTLA-4 engagement inhibits 1L-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med, 1996, 183(6):2533-2540.
  • 9Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol, 2002, 3(11): 1097-1101.
  • 10Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med, 2000, 192(2):303-310.

二级参考文献24

  • 1毛海婷,王雄彪,张玲,顾洪涛.CTLA-4基因多态性在重症肌无力发病机理中的作用[J].中华医学遗传学杂志,2004,21(6):574-578. 被引量:13
  • 2莫雪安,陈莉,李劲频,刘竞丽,马朝桂.抗CD40配体单克隆抗体干预重症肌无力的研究[J].中华神经科杂志,2005,38(2):98-100. 被引量:3
  • 3毛海婷,王雄彪,张玲,顾洪涛.CTLA-4在重症肌无力患者中的表达及其多态性导致的无效转录研究[J].中华微生物学和免疫学杂志,2005,25(4):257-262. 被引量:6
  • 4ALEGRE ML,FALLARINO F.Mechanisms of CTLA-4-Ig in Tolerance Induction[J].Curr Pharm Des(S1381-6128),2006,12(2):149-160.
  • 5MCINTOSH KR,LINSLEY PS,DRACHMAN DB.Immunosuppression and Induction of Anergy by CTLA4Ig in Vitro:Effects on Cellular and Antibody Responses of Lymphocytes from Rats with Experimental Autoimmune Myasthenia Gravis[J].Cell Immunol(S0008-8749),1995,166(1):103-112.
  • 6IM SH,BARCHAN D,MAITI PK,et al.Blockade of CD40 Ligand Suppresses Chronic Experimental Myasthenia Gravis by Down-Regulation of Th1 Differentiation and Up-Regulation of CTLA-4[J].The Journal of Immunology(S0022-1767),2001,166:6893-6898.
  • 7SCOTT BG,YANG H,TUZUN E,et al.ICOS Is Essential for the Development of Experimental Autoimmune Myasthenia Gravis[J].J Neuroimmunol(S0165-5728),2004,153(1-2):16-25.
  • 8ONODERA J,NAGATA T,FUJIHARA K,et al.Expression of OX40 and OX40 Ligand (gp34) in the Normal and Myasthenic Thymus[J].Acta Neurol Scand(S0065-1427),2000,102(4):236-243.
  • 9XIAOYAN Z,PIRSKANEN R,MALMSTROM V,et al.Expression of OX40 (CD134) on CD4^+ T-cells from Patients with Myasthenia Gravis[J].Clin Exp Immunol(S0009-9104),2006,143(1):110-116.
  • 10TESAR V,JELINKOVA E,JIRSA M,et al.Soluble Adhesion Molecules and Cytokines in Patients with Myasthenia Gravis Treated by Plasma Exchange[J].Blood Purif(S0006-4971),2000,18(2):115-120.

同被引文献11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部